BDTX Stock Hits 52 Week High: Is There More Room for Growth?

Key Takeaways Black Diamond hit a 52-week high of $4.1 on Oct. 8, soaring 86.4% year to date.Silevertinib showed durable responses and good tolerability in phase I EGFRm NSCLC data.BDTX focuses solely on silevertinib after outlicensing BDTX-4933 to Servier Pharmaceuticals.Black Diamond Therapeutics, Inc. (BDTX) performance has been outstanding in 2025. Shares of this clinical-stage oncology company hit a 52-week high of $4.1 on Oct. 8.Year to date, BDTX shares have skyrocketed 86.4% compared with the indust ...